BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avandia rosiglitazone: Postmarketing study data

Last September, FDA significantly restricted the use of Avandia while EMA suspended the drug's marketing authorization due to cardiovascular safety concerns (see BioCentury, Sept. 27, 2010). GlaxoSmithKline markets Avandia, while Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) markets Actos.

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London,...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >